Frazier Life Sciences Management, L.P. Avidity Biosciences, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.59 Billion
- Q1 2025
A detailed history of Frazier Life Sciences Management, L.P. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 525,000 shares of RNA stock, worth $24.3 Million. This represents 0.98% of its overall portfolio holdings.
Number of Shares
525,000Holding current value
$24.3 Million% of portfolio
0.98%Shares
2 transactions
Others Institutions Holding RNA
# of Institutions
245Shares Held
116MCall Options Held
289KPut Options Held
998K-
Janus Henderson Group PLC London, X011.4MShares$529 Million0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.3MShares$525 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA9.68MShares$448 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.24MShares$428 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.75MShares$405 Million4.23% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $2.41B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...